TearSolutions' lead product, called Lacripep, delivers what no other approved or pipeline drug has been able to: rapid healing of the ocular surface and relief of dry eye symptoms with a best-in-class safety and comfort profile. This was all proven in their first-in-human clinical trial which has led to formal written FDA alignment on our clinical and regulatory path to an unrestricted general Dry Eye indication (which is the same path a dry eye drug called Xiidra took, which sold to Novartis for $5.3B).
The company is raising capital to get Lacripep back into the clinic for the first of two Phase III trials.
RiskLD is a physician-led startup out of Cleveland focused on improving maternity outcomes.
NXgenPort (NGP), has designed an innovative and transformative technology to maximize remote care in cancer patients requiring an implantable chemo-port catheter. Combining proven chemo-port...
Dr. Gupta is very active working with innovative startups across medical device and digital health and serves as a Sr. Clinical Advisor with AngelMD...
